共 9 条
[1]
Balfour J.A., Fauids D., Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections, PharmacoEconomics, 3, pp. 398-421, (1993)
[2]
Clinical Infectious Diseases, 15, (1992)
[3]
European guidelines for the clinical evaluation of anti-infective drug products, (1993)
[4]
Benfield P., Chrisp P., Imipenem/cilastatin: a pharmacoeconomic approach of its use in intra-abdominal infections, PharmacoEconomics, 1, pp. 443-459, (1992)
[5]
Davies P.G., Malek M.M., Parker S.E., Pharmacoenonomics of antibacterial treatment, PharmacoEconomics, 1, pp. 409-437, (1992)
[6]
Norrby S.R., Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review, Scandinavian Journal of Infectious Diseases, 60, pp. 74-78, (1988)
[7]
Norrby S.R., Eriksson M., Ottosson E., Imipenem-cilastatin versus gentamicin-clindamycin: a cost effectiveness study, Scandinavian Journal of Infectious Diseases, 18, pp. 371-374, (1986)
[8]
Pfister H.W., Preac-Mursic V., Wilske B., Schielkc E., Sorget F., Et al., Randomized comparison of eetriaxonc and cefotaxime in Lyme borreliosis, Journal of Infectious Diseases, 163, pp. 311-318, (1991)
[9]
Stamboulian D., Bonvehi P., Arevalo C., Bologna R., Cassetti I., Et al., Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci, Reviews of Infectious Diseases, 13, (1991)